CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Peter B Jones

OPENALEX: A5072392137↗ORCID: 0000-0002-0387-880X↗

Affiliations

Organizations

Cambridgeshire and Peterborough NHS Foundation Trustauthorship · GB Institute of Psychiatry and Neurologyauthorship · PL King's College Hospitalauthorship · GB King's College Londonauthorship · GB National Health Serviceauthorship · GB Smith Familyauthorship · AU University College Londonauthorship · GB University Hospitals Bristol NHS Foundation Trustauthorship · GB University of Bristolauthorship · GB University of Cambridgeauthorship · GB Yale Universityauthorship · US

Public evidence

13 connected articles

Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic2021 · medRxiv Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMC The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.

Registered research

Connected studies

Body Project SMIL: Effectiveness of Virtually Delivered Body Project Groups to Prevent Eating Disorders Among Young Women With Psychiatric Illnessnct06893627

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

2021 · PubMed Central Open Access

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open Access

Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies2021 · PubMed Central Open Access

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Peter B Jones - Medical Cannabis Research Engine